About ZetaGen
ZetaGen is a Healthcare company based in Syracuse (United States) founded in 2017. It operates as a small molecule therapeutics for bone regeneration are developed. ZetaGen has raised $33.26 million across 7 funding rounds from investors including New York State, National Cancer Institute and Consolidated Investment Group. ZetaGen offers products and services including ZetaMet™, ZetaMet-P™, ZetaMAST™, and ZetaBase®. Its focus areas include Life Sciences, Orthopedics, Drugs and Diversified. Its legal entity is ZETAGEN THERAPEUTICS, INC. Its competitors include Horizon Therapeutics, Osteal Therapeutics, Angitia, Histogenics and Osiris and 4 more; 7 of its 9 listed competitors have raised funding.
Company details
ZetaGen was founded in 2017 and is based in Syracuse, United States. Small molecule-based therapeutics are developed by the company for bone regeneration, targeting injuries, procedures, and diseases. A molecular pathway is activated by these drugs, while osteoclast activity is down-regulated to reduce bone destruction. Operations focus on the biotechnology sector, with emphasis on orthopedic applications.
- Headquarters Syracuse, United States
- SectorsHealthcare
- Website zetagen.com
- Social LinkedIn X
- Legal Name Zetagen Therapeutics, Inc.
- Total Equity Funding$33.26M (USD)
in 7 rounds
- Latest Funding Round$12.91M (USD), Series B
Oct 2025
- InvestorsNew York State
& 2 more
Products & Services of ZetaGen
ZetaGen offers a comprehensive portfolio of products and services, including ZetaMet™, ZetaMet-P™, ZetaMAST™, and ZetaBase®.
Therapy to suspend cancer and regenerate bone in patients.
Targets primary cancers with potential to minimize side effects.
Treats metastatic breast cancer to reduce tumor burden.
Aids in bone regeneration for cancer-related lesions.
Funding Insights of ZetaGen
ZetaGen has successfully raised a total of $33.26M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $12.91 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $33.26M
- Total Rounds 7
- Last Round Series B — $12.91M
- First Round $1M
(Dec 2018)
- Investors Count 3
All 7 funding rounds of ZetaGen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2025 | $12.91M | Series B | – | – | – |
| Jan 2025 | $83,186 | Series B | – | – | – |
| Aug 2023 | $9.79M | Series B | – | New York State, Consolidated Investment Group | – |
| Feb 2023 | $9.63M | Series A | – | – | – |
| Dec 2021 | $2M | Grant | – | – | |
| Dec 2019 | $840,000 | Seed | – | – | – |
| Dec 2018 | $1M | Debt – Conventional | – | – | – |
3 investors in total: 3 institutional.
Investors in ZetaGen
ZetaGen has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include New York State, National Cancer Institute and Consolidated Investment Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | ciginvest.com | - | |
Provides the information about government agencies in New York | – | ny.gov | United States | |
Cancer research is conducted and supported by the institute. | – | cancer.gov | Bethesda, United States |
Investor details for ZetaGen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ZetaGen
3 people are tracked at ZetaGen (3 in leadership).
| Name | Role | Group |
|---|---|---|
Bryan Margulies | Chief Scientific Officer and Co-founder | Leadership |
Joe Loy | CEO | Leadership |
Morakot Likhitpanichkul | Director of Scientific Operations | Leadership |
Complete people profiles for ZetaGen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ZetaGen
3 dated milestones of ZetaGen across 8 years, from founding to its latest funding, stage changes and deals.
- Founded ZetaGen is founded.
- Funding First funding round of $1.0M.
- Funding Latest funding round, Series B, of $12.9M.
Competitors of ZetaGen
ZetaGen has 9 listed competitors in our database, 7 of them funded. They include Horizon Therapeutics, Osteal Therapeutics, Angitia, Histogenics and Osiris, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| horizontherapeutics.com | 2008 | Dublin, Ireland | $61.78M | – | Developer of drugs for treating rare and autoimmune diseases | |
| ostealtx.com | 2013 | San Clemente, United States | $110.8M | – | Developer of pharmaceuticals for musculoskeletal therapeutics to treat orthopedic infections | |
| angitiabio.com | 2018 | Woodland Hills, United States | $276M | – | Drugs for muscle, bone, and joint diseases are developed. | |
| histogenics.com | 2000 | Waltham, United States | $115.72M | 69 | Restorative cell therapies for orthopedic diseases are developed. | |
| osiris.com | 1992 | Baltimore, United States | – | 356 | Stem cell-based regenerative medicines are developed and marketed. | |
| ingeneron.com | 2005 | Houston, United States | $51.4M | – | Advanced cell separation technologies are developed for regenerative cell preparation. | |
| enobia.com | 1997 | Quebec, Canada | $138.52M | – | Therapies for genetic metabolic bone disorders are developed. | |
| oscotec.com | 1998 | Cheonan, South Korea | – | – | Korean, clinical-stage, biopharma developing small molecule therapeutics for arthritis and cancer indications | |
| alestatherapeutics.com | 2021 | Leiden, Netherlands | $67.49M | – | Small molecule therapies for rare diseases are developed. |
Detailed competitors of ZetaGen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ZetaGen
The website of ZetaGen (zetagen.com) receives about 1.6K visits a month.
- Monthly visits1.6K
▼ 10.7% vs previous month
Top companies in Orthopedics
10 companies that operate in the same segment as ZetaGen (Orthopedics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Provider of high-frequency spinal cord stimulation implants | 2006 | Menlo Park, California, United States | USD 154.1 M | USD 353.08 M | 1,215 | |
Prosthetic and orthotic devices are developed for individuals with disabilities. | 1919 | Duderstadt, Lower Saxony, Germany | USD 17 M | USD 1.97 B | 4,125 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Developer of drugs for treating rare and autoimmune diseases | 2008 | Dublin, Ireland | USD 61.78 M | USD 617.41 M | – | |
Antibody-siRNA complexes are developed for cancer treatment. | 2012 | San Diego, California, United States | USD 142.54 M | USD 10.9 M | 391 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Robotic arms are provided for mobility and rehabilitation support. | 2004 | Boston, Massachusetts, United States | USD 17.21 M | USD 40.93 M | 185 | |
AI-powered drug discovery platform for various diseases | 2016 | New York, New York, United States | USD 608.25 M | – | 197 | |
Exoskeletons for medical rehabilitation and industrial productivity are provided. | 2005 | United States | USD 24.37 M | USD 71.6 M | 61 | |
Stabilization devices for healthcare are manufactured by the company. | 2005 | New York, New York, United States | USD 142.15 M | – | 43 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Zetagen
Complete news archive for ZetaGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ZetaGen
ZetaGen was founded in 2017 and raised its 1st funding round 1 year after it was founded.
ZetaGen is headquartered in Syracuse, United States. It is registered at Syracuse, New York, United States.
ZetaGen is a funded company, having raised a total of $33.26M across 7 funding rounds to date. The company's 1st funding round was a Debt – Conventional of $1M, raised on Dec 2018.
ZetaGen was founded in 2017 and is based in Syracuse, United States. Small molecule-based therapeutics are developed by the company for bone regeneration, targeting injuries, procedures, and diseases. A molecular pathway is activated by these drugs, while osteoclast activity is down-regulated to reduce bone destruction. Operations focus on the biotechnology sector, with emphasis on orthopedic applications.
ZetaGen's top competitors include Horizon Therapeutics, Angitia and Osiris.
ZetaGen offers ZetaMet™, ZetaMet-P™, ZetaMAST™, and ZetaBase®.
ZetaGen has 3 investors. Key investors include New York State, National Cancer Institute, and Consolidated Investment Group.
ZetaGen operates through Zetagen Therapeutics, Inc..